News

Immunotherapy may not phase out surgery and chemotherapy as standards of care in cancer, but oncolytic viruses may usher in a new age of treatment.

It's been an exciting year thus far for patients with neuroendocrine tumors, with the FDA approving a new treatment regimen and more advancements on the horizon.

Results of a phase I trial demonstrate that the combination of niraparib and bevacizumab can be safely administered to patients with platinum-sensitive relapsed ovarian cancer.

The management of medulloblastoma, the most common malignant brain cancer in children, has not changed in decades but breakthroughs are on the horizon.

The National Comprehensive Cancer Network has issued an updated recommendation for Optune for use in combination with temozolomide as standard treatment for patients with newly diagnosed glibolastoma multiforme.

Leptomeningeal metastases are more common in patients with non&ndash;small cell lung cancer who harbor <em>EGFR </em>mutations.&nbsp;Tyrosine kinase inhibitors were found to be the optimal treatment method for these patients, especially if they have not yet received a TKI treatment.

Across the fields of renal cell carcinoma, bladder cancer, and prostate cancer, immunotherapy agents are moving through the pipeline and impacting patient outcomes&mdash;some quicker than others.

The treatment paradigm of metastatic urothelial carcinoma was shaken up in May 2016 when the FDA approved the PD-L1 inhibitor atezolizumab for the treatment of patients with locally advanced or metastatic disease.

Atezolizumab proves to be non-toxic and shows major survival advantage in patients with metastatic urothelial bladder cancer.

Scientific breakthroughs can be difficult in a rare disease such as sarcoma, which makes up less than 1% of all adult cancers and comprises more than 50 subtypes.

Treatment with pembrolizumab led to a reduction of tumor size in 33% of patients with undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma.

Patients with renal cancer who underwent cytoreductive nephrectomy (CN) and targeted therapy (TT) had improved survival compared with patients who did not undergo the surgery, according to research from the Dana-Farber Cancer Institute and Brigham and Women&rsquo;s Hospital.¹&nbsp;Historically, only 3 in 10 such patients undergo the procedure.

The extended release injection formulation of granisetron (Sustol) has been approved by the FDA for use in combination with other antiemetic therapies for the prevention of chemotherapy-induced nausea and vomiting (CINV), according to Heron Therapeutics, the manufacturer of the treatment.

For patients with prostate cancer, prostatectomy&mdash;whether laparoscopic or robotic&mdash;can provide a significant clinical benefit.

Data from the phase I HD7 through HD11 trials proves promising enough to move on to phase II.

The pivotal phase III prostate cancer trial ARMO 3-SV will be discontinued based on recommendations made by the trial&#39;s independent data monitoring committee.

The FDA has placed a partial clinical hold on a planned pivotal trial examining NY-ESO SPEAR T-cell therapy in patients with myxoid round cell liposarcoma.

Over the past several years, the FDA approval of several novel agents has revolutionized the treatment of patients with metastatic castration-resistant prostate cancer.

Two-thirds of patients with chronic myeloid leukemia who ceased to receive the TKI treatment imatinib did not relapse after six months, according to Johan Richter, MD, PhD.

The FDA has approved the PD-1 inhibitor pembrolizumab as a second-line therapy for patients with recurrent or metastatic head and neck squamous cell carcinoma for those who have progression on a platinum chemotherapy.&nbsp;

Blinatumomab almost doubles the overall survival of patients with relapsed/refractory acute lymphoblastic leukemia, according to Max Topp, MD.

Understanding the roadblocks of immunotherapy in patients with newly diagnosed, metastatic pancreas cancer could provide oncologists with a new therapeutic tool to add to their armamentarium, according to Eileen O&#39;Reilly, MD.

A recent phase II trial examining nivolumab (Opdivo) in patients with anal cancer seeks to explore the biological makeup, and uncover potential biomarkers in anal cancer.

The CDK4/6 inhibitor ribociclib (LEE011) has received a breakthrough therapy designation from the FDA for its potential as a frontline therapy when given in combination with letrozole for patients with hormone-receptor (HR)-positive, HER2-negative advanced breast cancer.<br /> &nbsp;

Pracinostat has received a breakthrough therapy designation from the FDA, when given in combination with azacitidine, for the treatment of patients with newly diagnosed acute myeloid leukemia (AML) aged 75 years or older, or for those who are ineligible for intensive chemotherapy, according to MEI Pharma, the company developing pracinostat.

Although immunotherapies, such as nivolumab (Opdivo) and pembrolizumab (Keytruda), have generated great excitement in the field of squamous non-small cell lung cancer, a number of targeted agents are also gaining recognition.

Treatment with anthracyclines was proven to be beneficial for patients with high-risk, HER2-negative, early-stage breast cancer.

Early tumor shrinkage is linked to overall survival and could be a stronger surrogate marker than progression-free survival in metastatic colorectal cancer.

While the United States Preventative Services Task Force has taken a stand against routine prostate-specific antigen screening for prostate cancer, updated findings from the landmark Prostate, Lung, Colorectal, and Ovary screening trial could flip opinions.

Daratumumab (Darzalex) has been granted a breakthrough therapy designation by the FDA for use in the treatment of patients with multiple myeloma following at least 1 prior therapy. The CD38-targeted antibody is accepted for use in combination with lenalidomide/dexamethasone or bortezomib/dexamethasone, according to Janssen, which is developing daratumumab with Genmab.